Latest SenzaGen News & Updates

See the latest news and media coverage for SenzaGen. We track all announcements, press releases, and industry mentions in real time, all in one place.

SenzaGen

In vitro toxicology testing and regulatory advisory services

senzagen.com

Headquarters: Lund, Sweden
Founded year: 2010
Company type: Public company
Number of employees: 20–50
Industry: Business Support Services

Last updated Today

Latest news about SenzaGen

In short: SenzaGen reported 13% revenue growth in H1 2026 and reached record sales for its GARD technology while expanding its global market reach.

Company announcements

August 20 SenzaGen

SenzaGen reports 13% growth and positive cash flow in H1 2026

Revenue rose to SEK 15.3 million in Q2 2026 with positive operating cash flow. VitroScreen received major orders amid EU plans to phase out animal testing.

August 13 SenzaGen

SenzaGen celebrates OECD respiratory sensitization NAM advancement

The OECD report reviews current mechanistic understanding and regulatory needs, and discusses GARDair's role. SenzaGen contributed via Dr. Andy Forreryd and an international expert group.

June 5 SenzaGen

SenzaGen says EU roadmap boosts its long-term market potential

The European Commission's plan prioritizes sensitization testing fully by 2029, increasing demand for SenzaGen's GARD tests.

May 12 SenzaGen

SenzaGen reports 10% sales growth in Q1 2026 interim report

Net sales rose to SEK 15.0 million, with EBIT improving slightly. The company highlights increased attention to non-animal methods.

Media coverage

August 27 Investing.com

SenzaGen AB: news and analytics

SenzaGen shares plunge after unclear Q1 2025 report Investing.com — SenzaGen AB's recent first quarter 2025 report left...

August 20 Investing.com

SenzaGen Q2 revenue growth of 13%, VitroScreen subsidiary performance recovery

Investing.com -- Swedish non-animal testing company SenzaGen (transliteration: Sen Zhagen) announced that, driven by improved performance of its subsidiary VitroScreen, second-quarter revenue increased by 13% year-on-year to 15.3 million Swedish kronor. During the quarter, the company's operating loss narrowed, and earnings per share improved significantly compared to the same period last year. Cumulative revenue for the first half of the year reached 30.2 million Swedish kronor, with a loss per share of 0.13 Swedish kronor...

June 9 FinanzNachrichten.de

SenzaGen AB: SenzaGen's subsidiary receives two orders within non-animal testing with a total value of SEK 2.4 million

SenzaGen's subsidiary VitroScreen has received two orders from existing customers for non-animal testing. The total order value amounts to SEK 2.4 million, with the majority...

May 12 FinanzNachrichten.de

SenzaGen AB: SenzaGen's interim report January-March 2026 | 10% sales growth alongside increased attention to non-animal methods

"We started the year with 10 percent growth despite negative foreign exchange effects and the impact of a subsidiary undergoing a transition. At the same...

Never miss news about SenzaGen

Track SenzaGen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

SenzaGen competitors & trending companies

Browse news for competitors to SenzaGen and other trending companies.